Daily luteal serum and urinary hormone profiles in the menopause transition: Study of Women's Health Across the Nation.


Journal

Menopause (New York, N.Y.)
ISSN: 1530-0374
Titre abrégé: Menopause
Pays: United States
ID NLM: 9433353

Informations de publication

Date de publication:
02 2020
Historique:
pubmed: 4 12 2019
medline: 11 11 2020
entrez: 4 12 2019
Statut: ppublish

Résumé

To further characterize the endocrinology of the menopause transition, we sought to determine: whether relationships between urine and serum hormones are maintained as women enter their sixth decade; whether a single luteal phase serum progesterone (P) is reflective of integrated-luteal urinary pregnanediol glucuronide (uPdg); and whether serum P, like luteal uPdg, declines as women approach their final menses (FMP). The Study of Women's Health Across the Nation (SWAN) Daily Hormone Study's (DHS) is a community-based observational study. A subset of participants underwent a timed, luteal blood draw planned for cycle days 16 to 24 during the same month of DHS collection. Serum-luteinizing hormone (LH), follicle-stimulating hormone (FSH), estradiol and P, and urine LH, FSH, estrone conjugates (E1c), and daily and integrated luteal uPdg were measured in 268 samples from 170 women. Serum/urine hormone associations were determined using Pearson's correlation and linear regression, adjusted for concurrent age, body mass index, smoking status, and race/ethnicity. Pearson's r ranged from 0.573 (for LH) to 0.843 (for FSH) for serum/urine correlations. Integrated luteal uPdg weakly correlated with serum P (Pearson's r = 0.26, P = 0.004) and explained 7% of the variability in serum P in adjusted linear regression (total R 0.09, P = 0.002). Serum P demonstrated a marginally significant decline with approaching FMP in adjusted analysis (P = 0.04). Urine and serum hormones maintain a close relationship in women into their sixth decade of life. Serum luteal P was weakly reflective of luteal Pdg excretion.

Identifiants

pubmed: 31794501
doi: 10.1097/GME.0000000000001453
pmc: PMC7050767
mid: NIHMS1540226
doi:

Substances chimiques

pregnanediol-3 alpha-glucuronide 1852-49-9
Progesterone 4G7DS2Q64Y
Estradiol 4TI98Z838E
Luteinizing Hormone 9002-67-9
Follicle Stimulating Hormone 9002-68-0
Pregnanediol JR3JD1Y22C

Types de publication

Journal Article Observational Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

127-133

Subventions

Organisme : NIA NIH HHS
ID : U01 AG012554
Pays : United States
Organisme : NCRR NIH HHS
ID : UL1 RR024131
Pays : United States
Organisme : NIA NIH HHS
ID : U01 AG012495
Pays : United States
Organisme : NIA NIH HHS
ID : U01 AG012505
Pays : United States
Organisme : NIA NIH HHS
ID : U01 AG012531
Pays : United States
Organisme : NIA NIH HHS
ID : U01 AG012535
Pays : United States
Organisme : NIA NIH HHS
ID : U01 AG012553
Pays : United States
Organisme : NINR NIH HHS
ID : U01 NR004061
Pays : United States
Organisme : NIA NIH HHS
ID : U01 AG012539
Pays : United States
Organisme : NIA NIH HHS
ID : U01 AG012546
Pays : United States

Commentaires et corrections

Type : CommentIn

Références

Fertil Steril. 2010 Mar 1;93(4):1074-9
pubmed: 19100532
Ginekol Pol. 2014 Oct;85(10):771-7
pubmed: 25546929
Maturitas. 1989 Dec;11(4):331-9
pubmed: 2515421
Indian J Clin Biochem. 2006 Sep;21(2):90-4
pubmed: 23105621
J Clin Endocrinol Metab. 1996 Apr;81(4):1495-501
pubmed: 8636357
BMC Res Notes. 2018 Jan 22;11(1):61
pubmed: 29357944
J Clin Endocrinol Metab. 2008 Apr;93(4):1186-94
pubmed: 18252789
Am J Epidemiol. 1998 Jun 1;147(11):1071-80
pubmed: 9620051
Environ Health Perspect. 1996 Apr;104(4):408-13
pubmed: 8732951
Clin Chem. 1991 Jun;37(6):838-44
pubmed: 2049848
J Clin Endocrinol Metab. 2003 Apr;88(4):1516-22
pubmed: 12679432
Clin Chem. 2002 Sep;48(9):1584-6
pubmed: 12194939
Obstet Gynecol Clin North Am. 2018 Dec;45(4):723-736
pubmed: 30401553
J Clin Endocrinol Metab. 2018 Jul 1;103(7):2743-2751
pubmed: 29767754
J Clin Endocrinol Metab. 2004 Jun;89(6):2622-31
pubmed: 15181033
Am J Physiol Endocrinol Metab. 2003 Mar;284(3):E521-30
pubmed: 12441312
J Clin Endocrinol Metab. 2017 Jul 1;102(7):2218-2229
pubmed: 28368525
Obstet Gynecol Clin North Am. 2018 Dec;45(4):679-694
pubmed: 30401550

Auteurs

Nanette Santoro (N)

Department of Obstetrics and Gynecology, University of Colorado School of Medicine, Aurora, CO.

Samar R El Khoudary (SR)

Epidemiology Data Center, University of Pittsburgh, Pittsburgh, PA.

Alexis Nasr (A)

Epidemiology Data Center, University of Pittsburgh, Pittsburgh, PA.

Ellen B Gold (EB)

Department of Public Health Sciences, University of California Davis, Davis, CA.

Gail Greendale (G)

Department of Medicine, University of California at Los Angeles/David Geffen School of Medicine, Los Angeles, CA.

Dan McConnell (D)

Core Ligand Assay Satellite Services (CLASS) Laboratories, University of Michigan, Ann Arbor, MI.

Genevieve Neal-Perry (G)

Department of Obstetrics and Gynecology, University of Washington School of Medicine, Seattle, WA.

Jelena Pavlovic (J)

Department of Neurology, Albert Einstein College of Medicine, Bronx, New York, NY.

Carol Derby (C)

Department of Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, NY.

Sybil Crawford (S)

Department of Medicine, University of Massachusetts Medical Center, Worcester, MA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH